Results announcement for the third quarter 2013

Wednesday 23 October

GSK announces Q3 core EPS growth of 16% and dividend of 19p

  • Core EPS 28.9p (+16%) benefiting from operating, financial and long-term cost efficiencies
  • Pharma & Vaccines sales flat: US +2%, Europe +5%, Japan +2% offset by EMAP -9%,
  • Consumer Healthcare +4%
  • Four approvals in three markets; Tivicay for HIV and FluLaval Q-IV vaccine for flu; Tafinlar for metastatic melanoma; Relvar Ellipta for asthma
  • Q3 dividend of 19p (+6%)
  • Full year 2013 guidance reaffirmed

View full Q3 2013 results (PDF)

More information including including CFO interview are available in the quarterly results section of this website.

This press release is intended for business journalists and analysts/investors. Please note that this release may not have been issued in every market in which GSK operates.